Evaxion Biotech announced a collaboration with Afrigen Biologics. The collaboration aims at developing a prophylactic vaccine based on Evaxion’s EDEN-discovered gonorrhea targets. The EDEN-discovered antigens have demonstrated high levels of protection in preclinical studies. This partnership will explore the expression and biological activity of the antigens in mRNA format. Following the validation phase, the partners will negotiate a subsequent agreement for clinical development and commercialization, with the opportunity to bring in additional partners.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EVAX:
- Evaxion Biotech expands preclinical bacterial vaccine pipeline, EVX-B3
- Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
- Evaxion Biotech announces vaccine discovery milestone
- Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
- Evaxion Biotech appoints Kanstrup as CEO